Search research articles
Contact Us
Filters
Showing results (21-30 of 32) with videos related to
Page
of 4
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
May 11, 2019
Relevance of tumour-infiltrating lymphocytes, PD-1 and PD-L1 in patients with high-risk, nodal-metastasised breast cancer of the German Adjuvant Intergroup Node-positive study
Aurelia Noske, Volker Möbus, Karsten Weber, et al.
Clinical Epigenetics
|
October 4, 2021
DNA methylation profiling identifies two distinct subgroups in breast cancers with low hormone receptor expression, mainly associated with HER2 amplification status
Philipp Jurmeister, Karsten Weber, Sonia Villegas, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|
December 23, 2017
Clinical relevance and concordance of HER2 status in local and central testing-an analysis of 1581 HER2-positive breast carcinomas over 12 years
Berit M Pfitzner, Bianca Lederer, Judith Lindner, et al.
Journal for Immunotherapy of Cancer
|
November 17, 2020
Differential effect on different immune subsets of neoadjuvant chemotherapy in patients with TNBC
Chiara Massa, Thomas Karn, Carsten Denkert, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 17, 2021
Immune-related Gene Expression Predicts Response to Neoadjuvant Chemotherapy but not Additional Benefit from PD-L1 Inhibition in Women with Early Triple-negative Breast Cancer
Bruno V Sinn, Sibylle Loibl, Claus A Hanusch, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 4, 2023
Inferred Immune-Cell Activity Is an Independent Predictor of HER2-Negative Breast Cancer Prognosis and Response to Paclitaxel-Based Therapy in the GeparSepto Trial
Peter A Fasching, Christopher Szeto, Carsten Denkert, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 14, 2019
Mutational Diversity and Therapy Response in Breast Cancer: A Sequencing Analysis in the Neoadjuvant GeparSepto Trial
Sibylle Loibl, Denise Treue, Jan Budczies, et al.
NPJ Breast Cancer
|
April 13, 2026
Tumor mutations predict HER2-targeted therapy resistance in primary HER2-positive breast cancer
Marion T Van Mackelenbergh, Nicole Pfarr, Karsten Weber, et al.
Cancer Cell
|
February 24, 2023
Intratumoral CD8<sup>+</sup> T cells with a tissue-resident memory phenotype mediate local immunity and immune checkpoint responses in breast cancer
Balaji Virassamy, Franco Caramia, Peter Savas, et al.
JCO Precision Oncology
|
April 10, 2025
<i>BRCA1/2</i> and Other Predisposition Genes in High-Risk Hormone Receptor+/Human Epidermal Growth Factor Receptor 2- Breast Cancer Treated With Endocrine Therapy With or Without Palbociclib: A Secondary PENELOPE-B Study Analysis
Eric Hahnen, Jan Hauke, Karen Gelmon, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 32) with videos related to
Sort By:
Page
of 4
European Journal of Cancer (Oxford, England : 1990)
|
May 11, 2019
Relevance of tumour-infiltrating lymphocytes, PD-1 and PD-L1 in patients with high-risk, nodal-metastasised breast cancer of the German Adjuvant Intergroup Node-positive study
Aurelia Noske, Volker Möbus, Karsten Weber, et al.
Clinical Epigenetics
|
October 4, 2021
DNA methylation profiling identifies two distinct subgroups in breast cancers with low hormone receptor expression, mainly associated with HER2 amplification status
Philipp Jurmeister, Karsten Weber, Sonia Villegas, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|
December 23, 2017
Clinical relevance and concordance of HER2 status in local and central testing-an analysis of 1581 HER2-positive breast carcinomas over 12 years
Berit M Pfitzner, Bianca Lederer, Judith Lindner, et al.
Journal for Immunotherapy of Cancer
|
November 17, 2020
Differential effect on different immune subsets of neoadjuvant chemotherapy in patients with TNBC
Chiara Massa, Thomas Karn, Carsten Denkert, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 17, 2021
Immune-related Gene Expression Predicts Response to Neoadjuvant Chemotherapy but not Additional Benefit from PD-L1 Inhibition in Women with Early Triple-negative Breast Cancer
Bruno V Sinn, Sibylle Loibl, Claus A Hanusch, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 4, 2023
Inferred Immune-Cell Activity Is an Independent Predictor of HER2-Negative Breast Cancer Prognosis and Response to Paclitaxel-Based Therapy in the GeparSepto Trial
Peter A Fasching, Christopher Szeto, Carsten Denkert, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 14, 2019
Mutational Diversity and Therapy Response in Breast Cancer: A Sequencing Analysis in the Neoadjuvant GeparSepto Trial
Sibylle Loibl, Denise Treue, Jan Budczies, et al.
NPJ Breast Cancer
|
April 13, 2026
Tumor mutations predict HER2-targeted therapy resistance in primary HER2-positive breast cancer
Marion T Van Mackelenbergh, Nicole Pfarr, Karsten Weber, et al.
Cancer Cell
|
February 24, 2023
Intratumoral CD8<sup>+</sup> T cells with a tissue-resident memory phenotype mediate local immunity and immune checkpoint responses in breast cancer
Balaji Virassamy, Franco Caramia, Peter Savas, et al.
JCO Precision Oncology
|
April 10, 2025
<i>BRCA1/2</i> and Other Predisposition Genes in High-Risk Hormone Receptor+/Human Epidermal Growth Factor Receptor 2- Breast Cancer Treated With Endocrine Therapy With or Without Palbociclib: A Secondary PENELOPE-B Study Analysis
Eric Hahnen, Jan Hauke, Karen Gelmon, et al.
Page
of 4